Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALTNASDAQ:AUTLNASDAQ:EXOZNASDAQ:ZVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$5.46-0.5%$5.08$3.55▼$11.16$442.84M1.132.83 million shs2.28 million shsAUTLAutolus Therapeutics$2.26+8.1%$1.43$1.11▼$5.00$601.48M1.771.54 million shs3.13 million shsEXOZExozymes$13.68+0.6%$12.25$8.50▼$23.99$114.47MN/A17,796 shs4,319 shsZVRAZevra Therapeutics$8.83-1.3%$7.69$4.20▼$9.76$482.82M2.01650,157 shs499,155 shsFree Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune+1.29%0.00%+1.10%-1.79%-25.61%AUTLAutolus Therapeutics+0.97%+26.67%+57.14%+0.97%-50.12%EXOZExozymes-4.02%-2.86%+25.35%-5.75%+1,359,999,900.00%ZVRAZevra Therapeutics+0.90%+7.44%+11.88%+11.18%+90.43%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALTAltimmune2.5882 of 5 stars3.51.00.00.02.83.30.6AUTLAutolus Therapeutics2.6062 of 5 stars3.51.00.00.02.93.30.6EXOZExozymesN/AN/AN/AN/AN/AN/AN/AN/AZVRAZevra Therapeutics2.8384 of 5 stars4.60.00.00.03.21.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 3.00Buy$20.20269.96% UpsideAUTLAutolus Therapeutics 3.00Buy$9.32312.39% UpsideEXOZExozymes 0.00N/AN/AN/AZVRAZevra Therapeutics 3.11Buy$22.29152.39% UpsideCurrent Analyst Ratings BreakdownLatest EXOZ, AUTL, ZVRA, and ALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025ZVRAZevra TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform5/14/2025ZVRAZevra TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$25.00 ➝ $25.004/10/2025AUTLAutolus TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/3/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.004/1/2025AUTLAutolus TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.003/21/2025AUTLAutolus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$8.00 ➝ $6.003/18/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.003/14/2025ALTAltimmuneWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform3/13/2025ZVRAZevra TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$23.00 ➝ $25.003/13/2025ZVRAZevra TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $22.003/13/2025ZVRAZevra TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$20K22,142.21N/AN/A$2.75 per share1.99AUTLAutolus Therapeutics$9.01M66.75N/AN/A$0.64 per share3.53EXOZExozymesN/AN/AN/AN/AN/AN/AZVRAZevra Therapeutics$40.59M11.90N/AN/A$1.71 per share5.16Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$88.45M-$1.26N/AN/AN/A-199,076.92%-55.81%-50.60%8/6/2025 (Estimated)AUTLAutolus Therapeutics-$208.38M-$0.88N/AN/AN/AN/A-63.65%-36.54%8/14/2025 (Estimated)EXOZExozymesN/AN/A0.00∞N/AN/AN/AN/AN/AZVRAZevra Therapeutics-$46.05M-$1.90N/A44.15N/A-342.63%-159.54%-51.50%8/12/2025 (Estimated)Latest EXOZ, AUTL, ZVRA, and ALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ALTAltimmune-$0.35-$0.26+$0.09-$0.26$0.00 million$0.01 million5/13/2025Q1 2025ZVRAZevra Therapeutics-$0.21-$0.06+$0.15-$0.06$16.96 million$20.40 million5/12/2025Q1 2025EXOZExozymesN/A-$0.22N/A-$0.22N/AN/A5/8/2025Q1 2025AUTLAutolus Therapeutics-$0.24-$0.26-$0.02-$0.26$1.59 million$8.98 million3/20/2025Q4 2024AUTLAutolus Therapeutics-$0.21-$0.09+$0.12-$0.09$2.98 million$0.03 million3/11/2025Q4 2024ZVRAZevra Therapeutics-$0.39-$0.67-$0.28-$0.67$8.93 million$12.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/AAUTLAutolus TherapeuticsN/AN/AN/AN/AN/AEXOZExozymesN/AN/AN/AN/AN/AZVRAZevra TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmuneN/A16.8716.87AUTLAutolus TherapeuticsN/A13.6913.69EXOZExozymesN/AN/AN/AZVRAZevra Therapeutics0.842.882.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%AUTLAutolus Therapeutics72.83%EXOZExozymesN/AZVRAZevra Therapeutics35.03%Insider OwnershipCompanyInsider OwnershipALTAltimmune4.10%AUTLAutolus Therapeutics25.70%EXOZExozymesN/AZVRAZevra Therapeutics2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5081.11 million68.21 millionOptionableAUTLAutolus Therapeutics330266.14 million197.71 millionOptionableEXOZExozymes298.37 millionN/AN/AZVRAZevra Therapeutics2054.68 million52.10 millionOptionableEXOZ, AUTL, ZVRA, and ALT HeadlinesRecent News About These CompaniesNuveen Asset Management LLC Reduces Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)June 5 at 3:42 AM | marketbeat.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Purchased by Millennium Management LLCJune 3 at 3:29 AM | marketbeat.comZevra Therapeutics: Zevra Announces Final Results of 2025 Annual Meeting of StockholdersMay 31, 2025 | finanznachrichten.deZevra Therapeutics Stockholders Re-Elect Wendy L. Dixon, Ph.D. and Tamara A. Favorito to Board of Directors Amid Commitment to Growth StrategyMay 31, 2025 | nasdaq.comZevra Announces Final Results of 2025 Annual Meeting of StockholdersMay 29, 2025 | globenewswire.comCitizens JMP Reiterates Buy Rating on Zevra Therapeutics (ZVRA), Keeps PTMay 27, 2025 | insidermonkey.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Rating of "Buy" by AnalystsMay 27, 2025 | marketbeat.comNorthern Trust Corp Buys 81,252 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA)May 25, 2025 | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Upgraded to Buy at Wall Street ZenMay 24, 2025 | marketbeat.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Bought by Woodline Partners LPMay 23, 2025 | marketbeat.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) is Velan Capital Investment Management LP's 9th Largest PositionMay 21, 2025 | marketbeat.comAll Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company's Director NomineesMay 21, 2025 | globenewswire.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Stock Holdings Lowered by Stonepine Capital Management LLCMay 20, 2025 | marketbeat.comQ2 EPS Forecast for Zevra Therapeutics Raised by AnalystMay 20, 2025 | marketbeat.comRoth Capital Lifts Earnings Estimates for Zevra TherapeuticsMay 18, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Flora Growth (FLGC), Cardinal Health (CAH) and Zevra Therapeutics (ZVRA)May 16, 2025 | theglobeandmail.comWith 49% stake, Zevra Therapeutics, Inc. (NASDAQ:ZVRA) seems to have captured institutional investors' interestMay 15, 2025 | finance.yahoo.comZevra Reports First Quarter 2025 Financial Results and Corporate UpdateMay 14, 2025 | taiwannews.com.twZevra Therapeutics, Inc. (ZVRA) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comZevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue EstimatesMay 13, 2025 | zacks.comZevra Therapeutics, Inc. Q1 2025 Earnings PreviewMay 12, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEXOZ, AUTL, ZVRA, and ALT Company DescriptionsAltimmune NASDAQ:ALT$5.46 -0.03 (-0.55%) Closing price 04:00 PM EasternExtended Trading$5.46 +0.00 (+0.02%) As of 05:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Autolus Therapeutics NASDAQ:AUTL$2.26 +0.17 (+8.13%) Closing price 04:00 PM EasternExtended Trading$2.28 +0.02 (+0.66%) As of 05:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.Exozymes NASDAQ:EXOZ$13.68 +0.08 (+0.59%) As of 02:45 PM EasterneXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.Zevra Therapeutics NASDAQ:ZVRA$8.83 -0.12 (-1.34%) Closing price 04:00 PM EasternExtended Trading$8.83 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast A New All-Time High Is Coming Soon for Credo Technology Group Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
